Inside NImmune’s Phase 3 Push in Ulcerative Colitis

Summary

In this episode, Dr. Josep Bassaganya‑Riera discusses NImmune's strategy to launch omilancor, a gut‑restricted LANCL2 agonist, into Phase 3 for ulcerative colitis, emphasizing its mechanism as an immune “thermostat” that rebalances gut immunity rather than broadly suppressing it. He highlights the company’s precision approach, using a gene‑expression biomarker to boost response rates from the typical 20% to potentially 33%‑50%, and explains how the TITAN‑X AI platform prospectively predicts trial outcomes and informs dosing and patient selection. The conversation also covers the challenges of building a late‑stage immunology company in a tighter capital environment, noting the continuity from Landos Biopharma and the importance of a focused, data‑driven clinical program.